Nutrition, Diabetes and Pulmonary TB/HIV
NCT00311298 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1250
Last updated 2009-08-04
Summary
We propose a randomised trial among pulmonary TB patients, examined and treated as part of the national TB control programme (WHO, 2003). The aim is to improve TB treatment outcome in high TB and HIV burden countries. The overall objective of the proposed trial is to assess the effect of nutritional support on TB treatment outcomes, and to assess the role of diabetes on risk and severity of TB, and TB treatment outcomes. The study will be conducted in Mwanza Tanzania. All patients will initially be examined for HIV and diabetes. A total of 500 found pulmonary TB smear-positive (PTB+) and HIV positive (HIV+) will be randomised to a daily supplement of 1 versus 6 energy-protein bars throughout treatment, both with full multi-micronutrient (MN) content. A total of 1500 found pulmonary TB smear-negative (PTB-, irrespective of HIV status) and PTB+ and HIV negative (HIV-) will be randomised to 1 daily energy-protein bar containing either low or high MN content.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Multimicronutrients
Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
- DIETARY_SUPPLEMENT
-
Energy and proteins
Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
Sponsors & Collaborators
-
National Institute for Medical Research, Tanzania
collaborator OTHER_GOV -
The Danish Medical Research Council
collaborator OTHER -
Danish Council for Development Research
collaborator OTHER -
University of Copenhagen
lead OTHER
Principal Investigators
-
Nyagosya Range, MSc, PhD · Muhimbili Medical Centre, NIMR
-
Henrik Friis, MD, PhD · University of Copenhagen
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-04-30
- Primary Completion
- 2009-03-31
- Completion
- 2009-03-31
Countries
- Tanzania
Study Locations
More Related Trials
-
Vitamin A Therapy for Tuberculosis
NCT00057434 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda
NCT00122941 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes
NCT01782950 ·Status: UNKNOWN ·Phase: PHASE4
-
Tuberculosis in HIV Infected Patients in Uganda
NCT00057421 ·Status: COMPLETED ·Phase: PHASE2
-
The Pediatric HIV Nutrition Study in Uganda
NCT02421302 ·Status: UNKNOWN ·Phase: NA
-
Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People
NCT00052195 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
NCT01252537 ·Status: COMPLETED
-
POC Strategies to Improve TB Care in Advanced HIV Disease
NCT04122404 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis
NCT00474435 ·Status: UNKNOWN ·Phase: PHASE2
-
Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda
NCT05640648 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenetics-guided Isoniazid Dosing in TB-HIV
NCT05124678 ·Status: UNKNOWN ·Phase: PHASE2
-
Enhanced TB Screening to Determine the Prevalence and Incidence of TB in Patients With HIV
NCT02043067 ·Status: COMPLETED
-
Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings
NCT00091936 ·Status: COMPLETED ·Phase: NA
-
Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries
NCT04781257 ·Status: ACTIVE_NOT_RECRUITING
-
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
NCT05917210 ·Status: RECRUITING ·Phase: NA
-
Study of Impacts of Food Supplementation on Malnourished HIV-Infected Adults in Kenya
NCT00838292 ·Status: COMPLETED ·Phase: NA
-
Interrupting HIV and TB Stigma in the Household in Uganda
NCT05124665 ·Status: COMPLETED ·Phase: NA
-
Rudi Kundini, Pamoja Kundini: Phase I
NCT05248100 ·Status: COMPLETED ·Phase: NA
-
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
NCT04121195 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
NCT05342064 ·Status: RECRUITING ·Phase: NA
-
A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi
NCT01356095 ·Status: COMPLETED ·Phase: NA
-
HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
NCT01141205 ·Status: COMPLETED ·Phase: PHASE1
-
Collection of Tissue Specimens in Mali, West Africa, for HIV and Tuberculosis Research
NCT00341042 ·Status: TERMINATED
-
Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV
NCT01529125 ·Status: COMPLETED
-
Multi-vitamins, HAART and HIV/AIDS in Uganda
NCT01228578 ·Status: COMPLETED ·Phase: PHASE3